Last November we covered the news that BME had seen improvements to its HammerLock hammertoe fixation device cleared by the FDA. A year on and we see HammerLock® 2; The Sequel, incorporating a raft of changes that make the procedure a simpler affair.
BioMedical Enterprises (BME) has announced the launch of the HammerLock 2 Intramedullary Nitinol Fixation System. This next generation HammerLock implant with its innovative Nitinol technology, now provides surgeons with an intramedullary implant that is designed to fit a wider range of hammertoe anatomies than its earlier iterations, and now does not require freezing. This significant advancement allows surgeons to take advantage of the compressive benefits of Nitinol fixation while simplifying the logistics inside the operating room.
Dr. Mark Myerson, Medical Director, The Institute for Foot and Ankle Reconstruction, Mercy Medical Center in Baltimore, MD stated, “I have used numerous intramedullary devices for stabilization of the proximal interphalangeal joint and the HL2 is by far the most predictable, versatile and reliable in my hands”.
“Our ability to innovate at this level is made possible by a company-wide team effort that includes a group of distinguished surgeon advisors, dedicated engineers and tireless manufacturing team that design, develop, prototype and test exciting new ideas on a daily basis. This process has allowed BME to become the premier company for shape memory fixation systems. We are all excited about the opportunity that HL2 presents and for the prospects for 2015.” said Keith M. Peeples, President and CEO of BME.
Source: BME, Inc., PR Newswire